NCE-1 Intelligence & Market Opportunity

Fabhalta

Iptacopan

Immunomodulators

Capsule

Fabhalta is an oral capsule that helps treat rare blood and kidney diseases by inhibiting complement factor B. It’s approved for adults with paroxysmal nocturnal hemoglobinuria (PNH), and to reduce proteinuria in complement 3 glomerulopathy (C3G) and IgA nephropathy.

Approval Date

05-Dec-23

NCE-1 Date

05-Dec-27

NCE Date

05-Dec-28

Commercial snapshot

Market performance & projections

Revenue ($M)

505

CAGR (%)

42.13%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

850

2027

1,252

2028

1,669

2029

2,061

2030

2,394

2031

2,711

2032

2,986

Molecule profile

Details & specifications

Molecule

Iptacopan

Innovator

NOVARTIS PHARMACEUTICALS CORP

Dosage Form

Capsule

Strength

200 mg

Therapeutic Category

Immunomodulators

Usage

To treat paroxysmal nocturnal hemoglobinuria

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets